Security
Kamada Ltd. Ordinary Shares · KMDA
KMDANASDAQCommon stockCurrentCIK 1567529Updated Oct 7, 2026
KMDA price & chart
Loading TradingView…
NASDAQ:KMDA on TradingView ↗About the company
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived …
In the news
No coverage from other publishers is available.
Seeking Alpha
AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure ↗
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript ↗
SEC disclosures
KAMADA LTD IPO declared effective by SEC ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | 20,198,000Source | 14,462,000Source | 8,284,000Source | -2,321,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | — | — | — | — |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -5,407,000Source | -1,977,000Source | 7,835,000Source | 7,603,000Source |
| AdjustmentsForFinanceCostsUSD | 2,766,000Source | — | — | — |
| AdjustmentsForIncomeTaxExpenseUSD | 3,269,000Source | -1,128,000Source | 145,000Source | 62,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -6,870,000Source | 1,226,000Source | -8,885,000Source | 7,055,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 845,000Source | 874,000Source | 1,314,000Source | 1,153,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesUSD | 11,534,000Source | — | — | — |
| GeneralAndAdministrativeExpenseUSD | 18,724,000Source | 15,702,000Source | 14,381,000Source | 12,803,000Source |
| GoodwillUSD | 30,313,000Source | 30,313,000Source | 139,955,000Source | — |
| InterestPaidClassifiedAsOperatingActivitiesUSD | 864,000Source | 594,000Source | 1,228,000Source | 853,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 1,921,000Source | 2,118,000Source | — | 97,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 972,000Source | 1,251,000Source | — | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | 8,000Source | 1,000Source | 7,000Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 17,407,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 1,807,000Source |
| Total RevenueUSD | 180,460,000Source | 10,000,000,000Source | 142,519,000Source | 129,339,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | — | — | 0.04Source |
| AverageEffectiveTaxRatenumber | 0.06Source | 0.06Source | — | 0.08Source |
| BasicEarningsLossPerShareUSD per share | 0.35Source | 0.25Source | 0.17Source | -0.05Source |
| CurrentTaxExpenseIncomeUSD | 1,260,000Source | 209,000Source | 145,000Source | 62,000Source |
| DeferredTaxExpenseIncomeUSD | 2,009,000Source | -1,337,000Source | — | — |
| DepreciationAndAmortisationExpenseUSD | 1,639,000Source | — | 1,244,000Source | 1,024,000Source |
| DilutedEarningsLossPerShareUSD per share | 0.35Source | 0.25Source | 0.15Source | -0.05Source |
| EmployeeBenefitsExpenseUSD | — | — | — | 238,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 845,000Source | 867,000Source | 1,314,000Source | 1,138,000Source |
| FinanceCostsUSD | 864,000Source | 660,000Source | 1,298,000Source | 914,000Source |
| FinanceIncomeUSD | 1,921,000Source | 2,118,000Source | 588,000Source | 91,000Source |
| GeneralAndAdministrativeExpenseUSD | 18,724,000Source | 15,702,000Source | 14,381,000Source | 12,803,000Source |
| GrossProfitUSD | 76,407,000Source | 69,967,000Source | 55,490,000Source | 46,703,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 3,269,000Source | -1,128,000Source | 145,000Source | 62,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | 21,145,000Source | 16,420,000Source | 148,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | 1,470,000Source | 925,000Source | 925,000Source | 873,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | — | 14,462,000Source | — | — |
| ProfitLossBeforeTaxUSD | 23,467,000Source | 13,334,000Source | 8,429,000Source | -2,259,000Source |
| ProfitLossFromOperatingActivitiesUSD | 26,233,000Source | 20,051,000Source | 10,064,000Source | 4,532,000Source |
| ResearchAndDevelopmentExpenseUSD | 12,995,000Source | 15,185,000Source | 13,933,000Source | 13,172,000Source |
Offerings
Registration 333-298814
Filing attachments
ea030767601ex99-1.htm · 6-K · 2026-10-06
Exhibit 99.1 Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate approximately $10 Million in Annual Revenue in 2028 and approximately $20 Million-$25 Million in Annual Revenue by 2030 REHOVOT, Israel, and Hoboken, NJ, - October 6, 2026 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA. TA), a global biopharmaceutical company with a portfol…
Read attachment ↗ea030770601ex99-1.htm · 6-K · 2026-10-05
Exhibit 99.1 Kamada Ltd. 2 Holzman Street St. Science Park, P.O. Box 4081, Rehovot 7670402 Israel VIA EDGAR October 5, 2026 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attn: Eric Atallah Bonnie Baynes Re: Kamada Ltd. Form 20-F for Fiscal Year Ended December 31, 2025 Filed March 11, 2026 ───────────────────────────────────────────────────── CIK No. 0001567529 Ladies and Gentleman: …
Read attachment ↗ea030573601ex99-1.htm · 6-K · 2026-09-17
Exhibit 99.1 CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB ® Supply to Meet Increased Demand U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kama…
Read attachment ↗ea030509101ex99-1.htm · 6-K · 2026-09-10
Exhibit 99.1 Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference REHOVOT, Israel, and Hoboken, NJ, - September 10, 2026 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA. TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Inves…
Read attachment ↗ea030461101ex99-1.htm · 6-K · 2026-09-03
Exhibit 99.1 Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel, and HOBOKEN, NJ - September 3, 2026 - Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA. TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA…
Read attachment ↗ea030232701ex99-1.htm · 6-K · 2026-08-17
Exhibit 99.1 Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 Dividend to be Paid Consistent with the Company’s Cash Dividend Policy REHOVOT, Israel, and HOBOKEN, NJ - August 17, 2026 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA. TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, t…
Read attachment ↗